Nevertheless, the first-in-class DM4-conjugated ADC, Mirvetuximab soravtansine, proved superior to chemotherapy with respect to progression-free and overall survival and objective remission rate in FRα-positive platinum-resistant ovarian cancer. The gene discussed is FOLR1; the disease is ovarian carcinoma.